Tekla Capital Management LLC
Q2 2023 13F Holdings
- Locationboston, MA
- Num holdings
166
- Value ($000)
$2,555,383
- Date Filed 08/10/2023
- Form type13F-HR
- CIK 0001300336
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q2 2023 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
A Amgen Inc. | COMMON | 031162100 | $136.88M | 5 % | 616,539 | ||
J Johnson & Johnson | COMMON | 478160104 | $119.47M | 5 % | 721,779 | ||
G Gilead Sciences, Inc. | COMMON | 375558103 | $118.22M | 5 % | 1,533,884 | ||
R Regeneron Pharmaceuticals, Inc. | COMMON | 75886F107 | $115.99M | 5 % | 161,418 | ||
V Vertex Pharmaceuticals Inc. | COMMON | 92532F100 | $111.92M | 4 % | 318,043 | ||
L Eli Lilly and Company | COMMON | 532457108 | $100.06M | 4 % | 213,352 | ||
U Unitedhealth Group Inc. | COMMON | 91324P102 | $99.47M | 4 % | 206,961 | ||
M Merck & Co., Inc. | COMMON | 58933Y105 | $84.02M | 3 % | 728,154 | ||
A AbbVie Inc. | COMMON | 00287Y109 | $73.51M | 3 % | 545,629 | ||
B Biogen Inc. | COMMON | 09062X103 | $70.63M | 3 % | 247,943 |
Rows Per Page
10
- 10
- 50
- 100